Half-year report · Q2
9273.TEDINET S100V85J
Period2024-07-01 → 2024-12-31
Filed2025-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥12.3bn | 2024-07-01 → 2024-12-31 | Cons. | Net sales |
| Revenue | ¥22.1bn | 2023-07-01 → 2024-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.4bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Operating income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Operating income |
| Operating income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥4.4bn | 2023-07-01 → 2024-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥3.1bn | 2024-07-01 → 2024-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.4bn | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.9bn | 2023-07-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.0bn | 2024-07-01 → 2024-12-31 | Cons. | Profit loss |
| Net income | ¥1.6bn | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Total assets | ¥33.6bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥32.0bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥29.6bn | at 2023-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥7.0bn | at 2024-12-31 | Cons. | Liabilities |
| Total liabilities | ¥7.0bn | at 2024-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥26.6bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥25.1bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥22.0bn | at 2023-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥12.5bn | at 2024-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.0bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥9.8bn | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.2bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.3bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.0bn | at 2023-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.0bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.8bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.5bn | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥3.7bn | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.5bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥644m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥738m | 2024-07-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥795m | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥639m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥48.66 | 2024-07-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.14 | 2023-07-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.46 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 79.1% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.3% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.2% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 28
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2024-12-31 | −¥604m |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2024-12-31 | ¥81m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥8.0bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥7.4bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.6bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2024-07-01 → 2024-12-31 | ¥4.9bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2024-07-01 → 2024-12-31 | ¥1.4bn |
| —segment total | revenue | 2024-07-01 → 2024-12-31 | ¥12.9bn |
| —segment total | revenue external | 2024-07-01 → 2024-12-31 | ¥12.3bn |
| —segment total | revenue intersegment | 2024-07-01 → 2024-12-31 | ¥604m |
| —segment total | segment profit | 2024-07-01 → 2024-12-31 | ¥3.0bn |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥871m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥38m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥7.9bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥7.0bn |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| jpcrp040300-q2r_E34071-000Drug Substance Sales Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥4.4bn |
| jpcrp040300-q2r_E34071-000Pharmaceutical Marketing Businessreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥1.0bn |
| —segment total | revenue | 2023-07-01 → 2023-12-31 | ¥12.3bn |
| —segment total | revenue external | 2023-07-01 → 2023-12-31 | ¥11.4bn |
| —segment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥871m |
| —segment total | segment profit | 2023-07-01 → 2023-12-31 | ¥2.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 494
| Item | Context | Value | Unit |
|---|---|---|---|
| Income taxes paid ope cf | Prior1YTDDuration | -795596000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -714368000 | JPY |
| Income taxes refund ope cf | Prior1YTDDuration | 91733000 | JPY |
| Income taxes refund ope cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 1540318000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 1008316000 | JPY |
| Purchase of noncurrent assets inv cf | Prior1YTDDuration | -628193000 | JPY |
| Purchase of noncurrent assets inv cf | CurrentYTDDuration | -1687552000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -91012000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -2649013000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 78011000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 634012000 | JPY |
| Other net inv cf | Prior1YTDDuration | -3125000 | JPY |
| Other net inv cf | CurrentYTDDuration | -2474000 | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -644320000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -3705028000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -150952000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -174952000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -475266000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -547234000 | JPY |
| Other net fin cf | Prior1YTDDuration | -12890000 | JPY |
| Other net fin cf | CurrentYTDDuration | -15686000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -639109000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -737872000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | -609000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | -9645000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | 256279000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -3444229000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 10035504000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 13195373000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 10291783000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 9751143000 | JPY |
| Directors compensations sga | Prior1YTDDuration | 110507000 | JPY |
| Directors compensations sga | CurrentYTDDuration | 116799000 | JPY |
| Salaries and allowances sga | Prior1YTDDuration | 280566000 | JPY |
| Salaries and allowances sga | CurrentYTDDuration | 282631000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 12928000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 13312000 | JPY |
| Provision for bonuses sga | Prior1YTDDuration | 26472000 | JPY |
| Provision for bonuses sga | CurrentYTDDuration | 24962000 | JPY |
| Provision for directors retirement benefits sga | Prior1YTDDuration | 6514000 | JPY |
| Provision for directors retirement benefits sga | CurrentYTDDuration | 5863000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 7010357000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | 4372585000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 11382942000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 11382942000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E34071-000DrugSubstanceSalesBusinessReportableSegmentsMember | 870846000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E34071-000PharmaceuticalMarketingBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 870846000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |